Chest Medicine
Another study shows Pfizer mRNA vaccine immunity is reduced over time.
2 Sep, 2021 | 10:05h | UTCWaning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar – medRxiv
Related:
Studies: COVID vaccine protection waning against infection but not hospitalization.
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.
Commentary on Twitter (thread – click for more)
The evidence of mRNA vaccine effectiveness (VE) waning grows: large Qatar experience shows substantial 5 month attrition for symptomatic infection VE below 50% and, to a lesser extent, vs hospitalization and deathhttps://t.co/4lIG68Bxm0 pic.twitter.com/rnyo0Si3RP
— Eric Topol (@EricTopol) August 27, 2021
RCT: Among critically ill patients, targeting oxygenation to a low-normal range vs. high-normal range did not result in a reduction in organ dysfunction.
2 Sep, 2021 | 08:23h | UTCEffect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial – JAMA (free for a limited period)
Related:
M-A of randomized trials: Conservative oxygen therapy for critically ill patients.
Oxygen administration for patients with ARDS – Journal of Intensive Care
Commentary on Twitter
Multicenter RCT found, among critically ill patients, targeting oxygenation to a low-normal range compared with a high-normal range did not result in a statistically significant reduction in organ dysfunction https://t.co/lEq28bqmM4 #ISICEM21
— JAMA (@JAMA_current) August 31, 2021
RCT: In patients with acute hypoxemic respiratory failure, a strategy of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal was not associated with improved outcomes.
2 Sep, 2021 | 08:21h | UTCEffect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial – JAMA (free for a limited period)
Related: Randomized Trial: Low vs Intermediate Tidal Volume Strategy in ICU Patients Without ARDS
Commentary on Twitter
In this randomized clinical trial that included 412 adults, 90-day mortality was 41.5% in the extracorporeal carbon dioxide removal group and 39.5% in the standard care group, a difference that was not statistically significant https://t.co/jhCY2r4qjX #ISICEM21
— JAMA (@JAMA_current) August 31, 2021
[Preprint] Pfizer vaccine booster dose protection: A nationwide study from Israel – “Twelve days or more after the booster dose we found an 11.4-fold decrease in the relative risk of confirmed infection, and a >10-fold decrease in the relative risk of severe illness”.
1 Sep, 2021 | 09:59h | UTCBNT162b2 vaccine booster dose protection: A nationwide study from Israel – medRxiv
Why is a third COVID-19 vaccine dose important for people who are immunocompromised?
1 Sep, 2021 | 09:57h | UTCRelated:
RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.
COVID may be most infectious 2 or 3 days around symptom onset.
1 Sep, 2021 | 09:51h | UTCCOVID may be most infectious 2 or 3 days around symptom onset – CIDRAP
Study: Patients, not staff, source of most hospital COVID spread.
1 Sep, 2021 | 09:52h | UTCStudy: Patients, not staff, source of most hospital COVID spread – CIDRAP
Original article: Superspreaders drive the largest outbreaks of hospital onset COVID-19 infections – eLife
Cohort study: A strategy combining a rapid antigen test and chest CT was effective in ruling out COVID-19 in the emergency department.
31 Aug, 2021 | 09:00h | UTC
Study demonstrates a significantly higher humoral immunogenicity induced by the SARS-CoV-2 Moderna vaccine compared with the Pfizer- BioNTech vaccine.
31 Aug, 2021 | 09:04h | UTCComparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 – JAMA
Related:
Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.
#ESCCongress – RCT: Influenza vaccination early after a myocardial infarction (MI) or in high-risk coronary heart disease resulted in a lower risk of a composite of all-cause death, MI, or stent thrombosis compared with placebo.
31 Aug, 2021 | 08:52h | UTCCommentaries:
IAMI: Influenza Vaccine Beneficial for Post-MI Patients – TCTMD
Influenza Vaccination After Myocardial Infarction – IAMI – American College of Cardiology
Flu vaccine after heart attack reduces risk of death – Cardiovascular Business
Commentary on Twitter
The IAMI trial showed that #fluvaccine within 72 hours of angiography/PCI/hospitalization among patients with recent #cvMI or high-risk coronary heart disease resulted in a salutary effect on CV outcomes at 12 months compared w/ placebo: https://t.co/csnS3G8vsa #ESCCongress pic.twitter.com/5JB4iUmMbV
— American College of Cardiology (@ACCinTouch) August 30, 2021
Study with over 29 million people in England shows Covid-19, not vaccination, presents biggest blood clot risks.
29 Aug, 2021 | 18:57h | UTCPress release: Covid-19, not vaccination, presents biggest blood clot risks – University of Oxford
Editorial: Strengthening international surveillance of vaccine safety – The BMJ
Commentaries:
Covid: Vaccine complications dwarfed by virus risks – BBC
Commentary on Twitter
#BMJInfographic Fast track research looked at patient level data for ~30 million people vaccinated in England and found that thrombosis risks associated with covid-19 vaccines are lower than that associated with covid-19 infection https://t.co/R0JlcuvMez @JuliaHCox pic.twitter.com/XMzXK6UOBc
— The BMJ (@bmj_latest) August 27, 2021
Cohort study: Patients with Covid-19 infected with the Delta variant are twice as likely to need hospital admission or emergency care attendance.
29 Aug, 2021 | 19:02h | UTCCommentaries:
Covid: Delta variant patients twice as likely to need hospital care – BBC
Covid-19 hospitalization risk doubles with Delta variant, UK study suggests – CNN
Commentary on Twitter
The Delta variant is bad enough, but there has been debate as to whether it, per se, carries a higher risk of hospitalization (H) beyond its very high contagiousness. A new, rigorous study shows a doubling of the H rate https://t.co/qom8l6fw4v pic.twitter.com/CwXPOU0YWi
— Eric Topol (@EricTopol) August 27, 2021
M-A: Factors associated with household transmission of SARS-CoV-2 – recent studies showed higher household secondary attack rates than earliest reports (13.4% vs. 31.1%); more transmissible variants and vaccines may lead to further changes.
29 Aug, 2021 | 18:48h | UTCCommentary: 1 in 5 people with COVID-19 pass it to others in household, study finds – UPI
Commentary on Twitter
The findings of this meta-analysis suggest that the household remains an important site of #SARSCoV2 transmission, and recent studies have higher household secondary attack rates estimates compared with the earliest reports. https://t.co/lFmkaz0zUe
— JAMA Network Open (@JAMANetworkOpen) August 27, 2021
New CDC Guidance says influenza and Covid vaccines can be given together – “COVID-19 vaccines and other vaccines may now be administered without regard to timing”
29 Aug, 2021 | 18:51h | UTCCommentary: Flu shot and a COVID jab? New 2021-2022 flu vaccine guidance points to both – McKnight’s
It’s not just SARS-CoV-2: Most respiratory viruses spread by aerosols.
27 Aug, 2021 | 10:18h | UTCOriginal article: Airborne transmission of respiratory viruses – Science
Commentary on Twitter (thread – click for more)
1/ AIRBORNE TRANSMISSION OF RESPIRATORY VIRUSES
A new peer-reviewed paper in @ScienceMagazine, reviewing the scientific literature on this topic. We conclude it is important not just for COVID-19, but also for other respiratory diseases such as the fluhttps://t.co/vik1deBzeB
— Prof. Jose-Luis Jimenez (@jljcolorado) August 26, 2021
[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.
27 Aug, 2021 | 10:11h | UTCPress release: Is COVID vaccine protection fading? – ZOE Covid Study
Commentaries:
Covid infection protection waning in double jabbed – BBC
Cohort study: Most COVID-19 hospital survivors had a good physical and functional recovery after 1 year of follow-up, but around half of the patients had at least one sequelae symptom.
27 Aug, 2021 | 10:13h | UTC1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study – The Lancet
Editorial: Understanding long COVID: a modern medical challenge – The Lancet
Related:
M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
New guidelines to help doctors manage long COVID patients published.
[Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.
27 Aug, 2021 | 10:16h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/andrew_croxford/status/1430799815693250562
Covid-19 vaccines flirted with perfection at first. Reality is more complicated.
27 Aug, 2021 | 10:05h | UTCCovid-19 vaccines flirted with perfection at first. Reality is more complicated – STAT
Commentary on Twitter
The mixed blessing of the 95% VE: When Pfizer & Moderna reported late last year that their Covid vaccines were highly effective, our expectations for these vaccines soared. It's time for us to get more realistic about what the vaccines can do. https://t.co/BFpje2qRmS
— Helen Branswell 🇨🇦 (@HelenBranswell) August 25, 2021
COVID-19 associated Mucormycosis: risk factors and mechanisms of disease.
27 Aug, 2021 | 10:07h | UTCRelated: Clinical Picture: Mucormycosis after COVID-19 in a patient with diabetes. (several articles on the subject)
Commentary on Twitter
🆕💥💥Review Article #CID @IDSAInfo @jobadd
COVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease #IDTwitter #medtwitter #TwitteRx https://t.co/Ob89SFNoPx pic.twitter.com/tzf7KpGVyG— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) August 22, 2021
Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.
26 Aug, 2021 | 09:16h | UTCCommentaries on Twitter
For those who still believe getting Covid-19 is less risky than taking the vaccine, take a look at this chart from an observational study of nearly 1 million people in Israel. The risk of these conditions is much higher in those infected than vaccinated.https://t.co/Io08oFYRqW pic.twitter.com/57hOaoT5wQ
— Benjy Renton (@bhrenton) August 25, 2021
(thread from the author – click for more)
1/
Vaccine safety: We compared excess adverse events after #COVID19 vaccination (Pfizer-BioNTech) and after documented #SARSCoV2 infection.https://t.co/PNyCTqkq0tTake-home message: Low excess risk of adverse events after vaccination, higher after infection.
Some thoughts👇 pic.twitter.com/pbpJwCRd3D
— Miguel Hernán (@_MiguelHernan) August 25, 2021
WHO Guide | Support for rehabilitation: self-management after COVID-19-related illness.
26 Aug, 2021 | 09:21h | UTC
Commentary on Twitter
The World Health Organisation have just published: Support for rehabilitation: self-management after COVID-19-related illness, 2nd ed. Written by the Leeds Rehabilitation team. Accessed from https://t.co/Ep4KG2FTiQ Will be in all European languages soon.
— Derick Wade (@derickwaderehab) August 25, 2021
Johnson & Johnson booster shot prompts large increase in immune response, company says.
26 Aug, 2021 | 09:14h | UTCJohnson & Johnson booster shot prompts large increase in immune response, company says – CNN
News release: Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease.
26 Aug, 2021 | 08:59h | UTCInvited commentary: Charting a course for the management of long COVID
Related: M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
Commentary on Twitter
NEW Position Paper—The long-term sequelae of #COVID19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease
From the International COVID-19 Airways Diseases Group https://t.co/QAoUhzbYtb pic.twitter.com/jj4rxEGyzC
— The Lancet Respiratory Medicine (@LancetRespirMed) August 18, 2021
New guidelines to help doctors manage long COVID patients published.
26 Aug, 2021 | 09:01h | UTCNew guidelines to help doctors manage long COVID patients published – Imperial College London
Original article: Recommendations for the recognition, diagnosis, and management of long covid: A Delphi study – British Journal of General Practice
Related: M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)